Option chain shows key data for China Health Technology's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for China Health Technology.

China Health Technology (OTC:CHBOF) Stock, Option Chain

China Health Technology Group Holding Co Ltd Formerly China Bozza Development Holdings Ltd is an investment holding company. It is engaged in the business of management of new agriculture and forestry resources in the People's Republic of China. The company has two reportable segments including the Forestry business; Horny Goat Weed Business; and Ginseng Business. The forestry management business includes plantation, logging, and sale of timber-related products and the Ginseng Business includes ginseng plantation and trading of related products. The company generates a majority of its revenue from the Forestry business segment. Geographically company generates its key revenue from the PRC.

CHINA BOZZA DEVPT LTD by CHINA BOZZA DEVELOPMENT HOLDINGS LTD.

China Health Technology Group Holding Co Ltd

WIIM

Weyerhaeuser shares are trading higher after CIBC upgraded the stock from Neutral to Outperformer.

BlackRock shares are trading higher after the company reported better-than-expected Q4 financial results.

Wedbush analyst Nick Setyan reiterates Papa John's International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PZZA#NASDAQ">PZZA</a>) with a Outperform and maintains $60 price target.

News

Price Target

Reiteration

Analyst Ratings

PZZA

Wedbush Reiterates Outperform on Papa John's International, Maintains $60 Price Target

<a href="https://www.bloomberg.com/news/articles/2025-01-15/netapp-selling-some-software-assets-to-thoma-bravo-s-flexera?utm_medium=social&amp;utm_source=twitter&amp;utm_content=business&amp;cmpid=socialflow-twitter-business&amp;utm_campaign=socialflow-organic&amp;sref=ZoyErlU1" title="https://www.bloomberg.com/news/articles/2025-01-15/netapp-selling-some-software-assets-to-thoma-bravo-s-flexera?utm_medium=social&amp;utm_source=twitter&amp;utm_content=business&amp;cmpid=socialflow-twitter-business&amp;utm_campaign=socialflow-organic&amp;sref=ZoyErlU1">https://www.bloomberg.com/news/articles/2025-01-15/netapp-selling-some-software-assets-to-thoma-bravo-s-flexera?utm_medium=social&amp;utm_source=twitter&amp;utm_content=business&amp;cmpid=socialflow-twitter-business&amp;utm_campaign=socialflow-organic&amp;sref=ZoyErlU1</a>

Asset Sales

NTAP

Bloomberg Reported NetApp Selling Some Software Assets to Thoma Bravo's Flexera For ~$100M

VCEL

Vericel shares are trading lower after the company issued preliminary FY24 and Q4 net revenue below estimates.

Needham analyst Scott Berg reiterates Paylocity Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCTY#NASDAQ">PCTY</a>) with a Buy and maintains $220 price target.

PCTY

Needham Reiterates Buy on Paylocity Holding, Maintains $220 Price Target

TRX Gold Corporation Says In Q1 It Poured 4,841 Ounces Of Gold Compared With 4,927 Ounces YoY; Generating Revenue Of $12.5M Higher Than $9.4M YoY

Wells Fargo analyst Brandon Couillard upgrades CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) from Underweight to Equal-Weight and lowers the price target from $28 to $24.

Upgrades

CDNA

Wells Fargo Upgrades CareDx to Equal-Weight, Lowers Price Target to $24

Needham analyst Ryan MacDonald reiterates Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Buy and maintains $15 price target.

Needham Reiterates Buy on Evolent Health, Maintains $15 Price Target

Needham analyst Ryan MacDonald reiterates Privia Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRVA#NASDAQ">PRVA</a>) with a Buy and maintains $25 price target.

PRVA

Needham Reiterates Buy on Privia Health Gr, Maintains $25 Price Target

BMO Capital analyst Brian Pitz maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Outperform and raises the price target from $825 to $1000.

NFLX

BMO Capital Maintains Outperform on Netflix, Raises Price Target to $1000

VIAV

VIAVI Solutions Introduced The Teravm AI Ran Scenario Generator, The Evolution Of The Company's Market-leading Ran Intelligent Controller Test Platform

Bank of New York Mellon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) reported quarterly earnings of $1.72 per share which beat the analyst consensus estimate of $1.56 by 10.26 percent. This is a 33.33 percent increase over earnings of $1.29 per share from the same period last year. The company reported quarterly sales of $4.847 billion which beat the analyst consensus estimate of $4.653 billion by 4.17 percent. This is a 8.65 percent increase over sales of $4.461 billion the same period last year.

Earnings

Earnings Beats

Bank of New York Mellon Q4 2024 Adj. EPS $1.72 Beats $1.56 Estimate, Sales $4.847B Beat $4.653B Estimate

TD Securities analyst Aaron Macneil initiates coverage on TC Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TRP#TSX">TRP</a>) with a Buy rating and announces Price Target of C$73.

Initiation

TSX:TRP

TD Securities Initiates Coverage On TC Energy with Buy Rating, Announces Price Target of C$73

KROS

Keros Therapeutics Announces Additional Update On The Phase 2 TROPOS Trial: Company Says It Voluntarily Halted All Dosing In The TROPOS Trial Based On The Ongoing Safety Review Due To New Observations Of Pericardial Effusion Adverse Events

Needham analyst Joshua Reilly reiterates Verint Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) with a Buy and maintains $40 price target.

VRNT

Needham Reiterates Buy on Verint Systems, Maintains $40 Price Target

Trilogy Metals Announce The Positive Results Of Its Preliminary Economic Assessment Study Or The Bornite Copper Project In The Ambler Mining District Of Northwestern Alaska

Parsons Announced That It Has Initiated A Task Order Extension Supporting The San Diego Pure Water Program

Arthur Hayes, co-founder of cryptocurrency exchange&nbsp;BitMEX&nbsp;and Chief Investment Officer at&nbsp;Maelstrom&nbsp;Fund, stated that Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) will thrive regardless of any government support or regulatory clarity under the incoming Donald Trump administration.
What Happened: In an interview with Benzinga, Hayes questioned the narrative that cryptocurrency-friendly regulations will serve as a bullish catalyst for the market
&#8220;Remember that we got to a total cryptocurrency market cap of over $3 trillion with no government support anywhere in the world. Why do we need it now?&#8221; Hayes argued.
As for Bitcoin, Hayes said that the leading cryptocurrency will flourish in spite of any regulations that would be enacted by Trump.
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42936962/shytoshi-kusama-outlines-treat-tokens-usefulness-ahead-of-launch-optimistic-whales-buy-up-shiba-inu">Shytoshi Kusama Outlines TREAT Token&#8217;s Usefulness Ahead Of Launch, Optimistic Whales Buy Up Shiba Inu</a>
Hayes expressed doubt on potential cryptocurrency-friendly policies under Trump, saying that most of them will only benefit his lobbyists and close advisors.
&#8220;I fear that the crypto regulation that Trump enacts will be a Frankenstein bill that is an inchoate mishmash of different policies desired by this or that close advisor or large campaign donor,&#8221; he said.
&#8220;It will be a gift to lobbyists and lawyers and will not ultimately bring that much clarity, as it will be impossible to comply with unless you have hundreds of millions of dollars to spend on lawyers.&#8221;
Hayes has been a long-time Bitcoin bull, projecting the apex cryptocurrency to hit $1 million in the long term. 
Why It Matters: Hayes&#8217; remarks come at a time when the incoming Trump administration is expected to significantly alter the landscape of cryptocurrency regulation. 
Recent reports suggested that Trump could issue <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42962279/trump-could-sign-crypto-related-executive-orders-on-day-1-report">executive orders on day one of his presidency</a>, possibly addressing de-banking and&nbsp;<a href="https://www.benzinga.com/24/12/42502213/new-crypto-accounting-standards-from-todaywill-it-boost-bitcoins-corporate-adoption" target="_blank" rel="noreferrer noopener">fair value accounting</a>, which requires banks holding cryptocurrencies to count them as liabilities on their balance sheet.
Trump has rewarded supporters with high-level appointments in the incoming administration. He named venture capitalist David Sacks, who held a <a href="https://www.benzinga.com/24/12/42356067/venture-capitalist-david-sacks-appointed-as-white-house-ai-crypto-czar-by-trump">fundraising event for Trump&#8217;s campaign</a> at his home, as the &#8220;White House A.I. &amp; Crypto Czar.&#8221;
Price Action: At the time of writing, Bitcoin was exchanging hands at $93,573.37, down 0.90% in the last 24 hours, according to&nbsp;<a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42935597/mark-cuban-advocates-bitcoin-over-gold-during-economic-turmoil-i-think-it-has-more-value-than-gold">Mark Cuban Advocates Bitcoin Over Gold During Economic Turmoil: &#8216;I Think It Has More Value Than Gold&#8217;</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Government

Regulations

Exclusives

Markets

$BTC

MSTR

Trump's Crypto Legislation Will Be A 'Frankenstein' Bill Of Mishmash, Says Arthur Hayes — Bitcoin Doesn't Need Government Support To Flourish

TD Securities analyst Aaron Macneil initiates coverage on Enbridge (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ENB#TSX">ENB</a>) with a Buy rating and announces Price Target of C$66.

Comments

China Health Technology

China Health Technology (CHBOF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga